3 Quotes by Jennifer Chao

Vaccines are beginning to be viewed as a much more attractive business compared to five years ago.

We anticipate Amgen to serve Roche an official court summons towards 3/06 timeframe upon which Roche will respond and the patent litigation suit will be in process. Ultimately, we continue to believe that Amgen will successfully defend its erythropoietin patents and that CERA will be found to have infringed.

It was a dramatic positive. The pie is bigger and the revenue slope is steeper.